KR100494808B1 - Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain - Google Patents
Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain Download PDFInfo
- Publication number
- KR100494808B1 KR100494808B1 KR10-2003-0019277A KR20030019277A KR100494808B1 KR 100494808 B1 KR100494808 B1 KR 100494808B1 KR 20030019277 A KR20030019277 A KR 20030019277A KR 100494808 B1 KR100494808 B1 KR 100494808B1
- Authority
- KR
- South Korea
- Prior art keywords
- polysaccharide
- polysaccharides
- strain
- produced
- bacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 87
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 87
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 87
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 title claims abstract description 10
- 239000003674 animal food additive Substances 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 7
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940097043 glucuronic acid Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 240000000123 Bacillus sp. A8 Species 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 241000282898 Sus scrofa Species 0.000 abstract description 9
- 238000011084 recovery Methods 0.000 abstract description 9
- 239000002689 soil Substances 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 8
- 244000144977 poultry Species 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 abstract description 7
- 230000005965 immune activity Effects 0.000 abstract description 7
- 230000001079 digestive effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 241000193830 Bacillus <bacterium> Species 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000009326 ileitis Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 다당류를 생산하는 균주인 바실러스 속 에이8(Bacillus sp. A8), 이 균주로부터 생산되는 다당류 및 이의 용도에 관한 것으로서, 더욱 상세하게는 토양으로부터 다당류를 생산하는 신균주 바실러스 속 에이8[KCTC 10433BP]을 분리하고, 이 균주로부터 생산되며, 넓은 pH 범위의 안정성과 염과의 호화성(salts compatability)이 아주 높아 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하고, 또한 고기능성 다당류의 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있는 미생물성 다당류 및 이를 사료첨가제로 사용하는 용도에 관한 것이다.The present invention relates to Bacillus sp. A8, a strain that produces polysaccharides, to a polysaccharide produced from the strain and its use, and more particularly, to a strain of the new strain Bacillus sp. A8, which produces polysaccharides from soil. KCTC 10433BP], produced from this strain, has a high pH stability and high salts compatability, resulting in constant intestinal action and treatment of digestive disorders in industrial animals (swine, poultry, etc.). Microorganisms that are specific to enhancing effects and promoting recovery, and also inhibit the onset of diseases caused by the death of beneficial organisms by the misuse of antibiotics and the increase of resistance of pathogens due to the increased anti-potency due to the immune activity of high-functional polysaccharides. It relates to sex polysaccharides and their use as feed additives.
Description
본 발명은 다당류를 생산하는 균주인 바실러스 속 에이8(Bacillus sp. A8), 이 균주로부터 생산되는 에이8(A8) 다당류 및 이의 용도에 관한 것으로서, 더욱 상세하게는 토양으로부터 수용성 다당류를 생산하는 신균주 바실러스 속 에이8을 분리하고, 이 균주로부터 생산되며, 넓은 pH 범위의 안정성과 염과의 호화성(salts compatability)이 아주 높아 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하고, 또한 고기능성 다당류의 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있는 미생물성 다당류 및 이를 사료첨가제로 사용하는 용도에 관한 것이다.The present invention relates to Bacillus sp. A8, a strain that produces polysaccharides, to A8 (A8) polysaccharides produced from the strain, and more particularly, to a method for producing water-soluble polysaccharides from soil. Isolates A8 genus B., which is produced from this strain, and has a high pH stability and high salts compatability, resulting in constant intestinal action and digestion of industrial animals (swine, poultry, etc.). It has a specific effect on increasing the therapeutic effect of the disorder and promoting recovery, and also suppresses the onset of disease caused by the death of enteric beneficial bacteria and the increase of resistance of pathogens due to the misuse of antibiotics due to the increase of the anti- potency due to the immune activity of high-functional polysaccharides. Microbial polysaccharides and their use as feed additives.
인위적인 환경에서 오랫동안 사육된 가축은 사료의 변화, 항생제 투여, 수송 및 운반, 스트레스, 유해미생물에 의한 감염 등에 영향을 받아 장내미생물간의 균형이 깨어져 증체율 및 사료의 소화효율의 저하 등이 발생되고 있다. 또한, 대장균과 살모넬라 등과 같은 병원균의 증식을 억제하고 가축성장을 촉진시키는 생균제로서 현재 가장 많이 이용되고 있는 유산균은 내산성과 내담즙성에 견디어야 하며, 생균제 자체의 밀도 역시 일정 수준을 유지하여야 하는 단점이 있다.Livestock raised for a long time in an artificial environment are affected by changes in feed, antibiotic administration, transport and transport, stress, infection by harmful microorganisms, and the balance between intestinal microorganisms is broken, resulting in a decrease in weight gain and digestion efficiency of feed. In addition, lactic acid bacteria, which are currently used as probiotics to inhibit the growth of pathogens such as Escherichia coli and Salmonella and promote livestock growth, must withstand acid resistance and bile resistance, and the density of probiotic itself must also be maintained at a certain level. have.
따라서, 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하며, 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있으며, 고품질의 청정 축산물을 안정적으로 생산하기 위한 새로운 다당류가 필요한 실정이다.Therefore, it acts specifically for the improvement of constant intestinal function and treatment of digestive disorders and promotion of recovery, and the disease caused by the death of beneficial organisms and the resistance of pathogens due to the misuse of antibiotics due to the increase of the anti-potency due to the immune activity. It is possible to suppress the onset, and new polysaccharides are needed to stably produce high quality clean livestock products.
이에, 본 발명자들은 상기와 같은 점을 감안하여 연구한 결과, 토양으로부터 신균주 바실러스 속 에이8을 분리하였으며, 이 균주로부터 넓은 pH 범위의 안정성과 염과의 호화성(salts compatability)이 아주 높아 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하는 고유의 물성을 가지며, 또한 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있으며, 고품질의 청정 축산물을 안정적으로 생산하여 산업동물의 가격 안정화의 기여에 이바지할 미생물성 다당류를 생산함으로써 본 발명을 완성하게 되었다.Therefore, the present inventors have conducted the study in view of the above, as a result, isolates A8 genus Bacillus A8 from the soil, the stability of a wide pH range and salts compatability with the salt is very high from this strain industry It has specific properties that specifically affect the intestinal constant action of the animal (swine, poultry, etc.) and increase the treatment effect of digestive disorders, and promote recovery. The present invention has been completed by producing microbial polysaccharides that can contribute to the stabilization of the price of industrial animals by stably producing high-quality clean livestock products by killing beneficial intestinal bacteria and increasing the resistance of pathogens. .
따라서, 본 발명은 신균주 바실러스 속 에이8[KCTC 10433BP] 및 이 균주로부터 생산되는 다당류를 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide a new strain Bacillus genus A8 [KCTC 10433BP] and polysaccharides produced from the strain.
또한, 본 발명은 상기 다당류를 포함하는 사료첨가제에 또 다른 특징이 있다. In addition, the present invention has another feature in the feed additive containing the polysaccharide.
본 발명은 다당류를 생산하는 바실러스 속 에이8(Bacillus sp. A8)[KCTC 10433BP]을 그 특징으로 한다.The present invention is characterized by Bacillus sp. A8 (KCTC 10433BP), which produces polysaccharides.
또한, 상기 균주로부터 생산되는 글루코오스(glucose), 퓨코오스(fucose), 글루쿠론산(glucuronic acid), 갈락토오스(galactose)로 구성된, 평균 분자량이 700만 달톤인 미생물성 다당류를 또 다른 특징으로 한다.In addition, the microbial polysaccharide having an average molecular weight of 7 million daltons, consisting of glucose, fucose, glucuronic acid, and galactose produced from the strain, is another feature.
이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.
본 발명은 토양으로부터 다당류를 생산하는 신균주 바실러스 속 에이8(Bacillus sp. A8)을 분리하고, 이 균주로부터 생산되며, 넓은 pH 범위의 안정성과 염과의 호화성(salts compatability)이 아주 높아 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하고, 또한 고기능성 다당류의 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있는 미생물성 다당류 및 이를 사료첨가제로 사용하는 용도에 관한 것이다.The present invention isolates Bacillus sp. A8 from the new strain Bacillus sp. A8, which produces polysaccharides from soil, and is produced from this strain, and has a high pH stability and high salts compatability. Intestinal activity caused by misuse of antibiotics due to the increase in the anti-tumor due to the immune activity of the high-functional polysaccharides and the specific intestinal function of the intestine of the animals (swine, poultry, etc.) The present invention relates to a microbial polysaccharide capable of inhibiting the development of diseases caused by the killing of beneficial bacteria and increased resistance of pathogens and the use of the same as a feed additive.
본 발명에 따른 신균주는 토양으로부터 세포외 미생물성 다당류를 생산하는 균주로 순수분리하여 형태학적, 생리학적, 생화학적으로 동정한 결과, 바실러스 속(Bacillus sp.)에 속하는 것으로 동정되었으며, 이를 바실러스 속 에이8(Bacillus sp. A8)로 명명하였다. 또한, 이 균주를 2003년 2월 24일에 한국생명공학연구원 유전자은행에 기탁하였으며, 수탁번호는 KCTC 10433BP로 부여받았다. 상기 균주는 토양에서 분리하여 일련의 과정을 거쳐 최종적으로 선별되었으며 바실러스 속으로 동정이 되었으나, 이제까지 보고된 유사균주와는 전혀 다른 물성학적 특성을 가진 다당류를 생산하는 균주이다.The new strain according to the present invention was identified as belonging to the genus Bacillus sp. As a result of morphological, physiological and biochemical identification by pure separation from the soil to produce extracellular microbial polysaccharides from the soil. Genus A8 ( Bacillus sp. A8) was named. In addition, the strain was deposited with the Korea Biotechnology Research Institute Gene Bank on February 24, 2003, and the accession number was assigned to KCTC 10433BP. The strain was separated from the soil and finally selected through a series of processes and identified as Bacillus, but is a strain that produces polysaccharides with physical properties that are completely different from similar strains reported so far.
또한, 상기 바실러스 속. 에이8[KCTC 10433BP]로부터 생산되는 신규 미생물성 다당류는 평균분자량이 700만 달톤 정도이며, 구성성분이 글루코오스(glucose), 퓨코오스(fucose), 글루쿠론산(glucuronic acid) 및 갈락토오스(galactose)를 함유하며, 구성 비율이 2.96 : 1.00 : 1.55 : 0.58 (몰비)이고, 세균이 생성하는 세포외 다당류들 중에서 이런 구성성분과 몰비를 가지는 다당류는 이제까지 보고된 바 없어 상기 다당류는 신규 다당류임이 확인되었다. 상기 다당류가 넓은 pH 범위의 안정성과 염과의 호화성(salts compatability)이 아주 높음을 확인함으로써 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적으로 작용하고, 또한 고기능성 다당류의 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있는 사료첨가제로 유용하게 사용될 수 있으리라 기대된다.Also, genus Bacillus. The new microbial polysaccharide produced from A8 [KCTC 10433BP] has an average molecular weight of about 7 million daltons, and its components include glucose, fucose, glucuronic acid and galactose. Among the extracellular polysaccharides produced by bacteria, the constituent ratio is 2.96: 1.00: 1.55: 0.58 (molar ratio), and polysaccharides having such a component and molar ratio have not been reported so far, and it has been confirmed that the polysaccharide is a novel polysaccharide. By confirming that the polysaccharide is stable in a wide range of pH and salts compatability is very high, it is specific to the constant intestinal effect of the intestines of industrial animals (swine, poultry, etc.) and to increase the therapeutic effect of digestive disorders and to promote recovery. In addition, it can be useful as a feed additive that can suppress the onset of disease caused by the increase of resistance of pathogens and the death of enteric beneficial bacteria due to the misuse of antibiotics due to the increase of the anti-tumor due to the immune activity of high-functional polysaccharides. It is expected.
이하, 본 발명은 다음 실시예에 의거하여 더욱 상세히 설명하겠는바, 본 발명이 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail based on the following examples, but the present invention is not limited thereto.
실시예 1: 다당류 생성 균주의 분리Example 1 Isolation of Polysaccharide Producing Strains
토양에서 시료를 채취하여 1g의 토양시료를 0.85% 생리식염수에 현탁하여 접종시료를 준비하였다. 고체배지인 엘비(LB, Tryptone 10 g, Yeast extract 5 g, NaCl 10 g/ℓD.W.) 배지에 생리식염수로 적당하게 희석한 접종시료액 100 ㎕를 도말하여 30 ℃에서 2 내지 3일간 배양하였다. 단일클로닌(single colony)으로 점액질을 분비하는 클로닌을 순수분리하여 무기염으로 구성된 다당류 생성 액체배지에 무균적으로 재접종하여 500 ㎖ 삼각플라스크로 3일 동안 배양하였다. 점도와 생성된 다당류의 생산량이 우수한 균주를 선별하였다.Samples were taken from the soil, and 1 g of soil samples were suspended in 0.85% saline to prepare an inoculation sample. Stain 100 µl of the inoculated sample diluted appropriately with physiological saline in the medium of LB (LB, Tryptone 10 g, Yeast extract 5 g, NaCl 10 g / ℓD.W.) And incubate at 30 ° C for 2 to 3 days. It was. Clonin, which secretes mucus as a single colony, was purely separated and aseptically reinoculated into a polysaccharide-producing liquid medium composed of inorganic salts and incubated with a 500 ml Erlenmeyer flask for 3 days. Strains with good viscosity and yield of the resulting polysaccharides were selected.
실시예 2: 균주 동정Example 2: Strain Identification
상기 실시예 1에서 분리한 균주의 형태학적 특성은 전자 현미경으로 관찰하였으며[도 1], 생화학적, 생리학적인 특성은 다음 표 1과 같다. 이 균주의 크기는 0.5 ∼ 0.7 ㎛ ×2.0 ∼ 2.5 ㎛인 간균이며[도 1], 운동성이 있었고 그람(Gram)양성이었다. 내생포자를 형성하며 O/F 시험에서는 산화(oxidation)와 발효(fermentation)이었다. 카탈라제(catalase)를 생성하지만 oxidase는 생성하지 않았고 혐기적 조건에서 느린 성장을 보였다. D-글루코스(D-glucose), D-자일로스(D-xylose), D-만니톨(D-mannitol)에서 산을 생성하였고 글루코스(glucose)에서 가스를 생성하였다. 카제인(Casein)을 분해한 반면에 젤라틴(gelatin), 전분(starch)을 분해하지 못하였고 인동(indol)은 형성하지 않았다. 7% NaCl에서 성장하지 못하였으며 45 ℃까지는 성장하였다. 이러한 결과를 Bergey's manual of systematic bacteriology[Peter, H.A.S., S.M. Nicolas, M.E. Sharp and J.G. Holt. 1986., vol. 2. Baltimore, London]와 Cowan과 Steel의 Manual of the identification of medical bacteria[Cowan, N.R., and K.J. Steel. 1965, Cambridge Univ. Press, London. Pp. 215]에 준하여 검토하고 비교 분석한 결과, 바실러스 코아구란과 유사하여 분리균주를 바실러스 속으로 동정하였다.Morphological characteristics of the strain isolated in Example 1 were observed with an electron microscope [FIG. 1], and biochemical and physiological characteristics are shown in Table 1 below. The strains were 0.5-0.7 μm × 2.0-2.5 μm bacilli [FIG. 1], which were motile and Gram positive. Endogenous spores were formed and in the O / F test, oxidation and fermentation were performed. It produced catalase but no oxidase and showed slow growth under anaerobic conditions. Acids were produced in D-glucose, D-xylose and D-mannitol and gas was produced in glucose. Casein was degraded while gelatin and starch were not degraded, and no indol was formed. It did not grow at 7% NaCl and grew up to 45 ° C. These results are described in Bergey's manual of systematic bacteriology [Peter, H.A.S., S.M. Nicolas, M.E. Sharp and J.G. Holt. 1986., vol. 2. Baltimore, London] and Cowan and Steel of Manual of the identification of medical bacteria [Cowan, N.R., and K.J. Steel. 1965, Cambridge Univ. Press, London. Pp. 215], the isolates were identified as Bacillus, similar to Bacillus coaguran.
또한, 이 균주의 16S rRNA를 이용하여 시퀀싱하고 염기서열을 비교 분석한 결과, 바실러스 섭틸리스와 99.8%의 상동성을 가짐을 확인하였다.In addition, by sequencing using the 16S rRNA of this strain and comparative analysis of the nucleotide sequence, it was confirmed that the homology with Bacillus subtilis of 99.8%.
이상의 결과로부터 본 분리균주는 바실러스 속과 유사한 성질을 갖는 근연균으로 동정되었으며, 이를 바실러스 속. 에이8(Bacillus sp. A8)로 명명하고, 이를 한국생명공학연구원의 유전자 은행에 2003년 2월 24일자로 기탁하여 수탁번호 KCTC 10433BP를 부여받았다.From the above results, the isolated strain was identified as mycorrhizal fungus with similar properties to the genus Bacillus, which is genus Bacillus. It was named A8 ( Bacillus sp . A8) and it was deposited on February 24, 2003 to the Gene Bank of Korea Research Institute of Bioscience and Biotechnology and was given accession number KCTC 10433BP.
실시예 3: 다당류 정제Example 3: Polysaccharide Purification
다당류를 생산하기 위하여 한국발효기의 5 리터 발효조(5 liter fermentor)를 사용하여 회분배양(batch culture)을 하였다. 배지조성은 글루코오스 30 g/L, NH4NO3 1 g/L, K2HPO4 1.2 g/L, KH2PO4 0.2 g/L, NaCl 0.1 g/L, MgSO4ㆍ7H2O 0.1 g/L, MnSO4ㆍH2O 0.1 g/L, FeSO4ㆍ7H2O 0.05 g/L로 조제하여 초기 pH 7 ∼ 8, 30 ℃에서 3일 동안 배양하였다. 발효조(jar fermentor)에서 배양이 완료된 배양액에서 균체를 분리하기 위해 배양액을 10배 희석하여 원심분리(12,000 ×g)하여 균체를 제거하였다. 균체를 제거한 상등액에 95% 에탄올을 상등액의 3배가 되도록 가하여 2시간 동안 4 ℃에서 방치하고 백색으로 침전물이 형성된 다당류를 분리하였다. 이렇게 분리된 다당류를 에이8(A8)로 명명하였다. 에이8 다당류를 증류수를 첨가하여 중탕하여 녹인 용액을 감압농축기(Evaporator)로 잔여 에탄올을 완전히 제거한 후에 동결건조하여 백색분말을 조제하였다.In order to produce polysaccharides, a batch culture was performed using a 5 liter fermentor of a Korean fermenter. Medium composition was glucose 30 g / L, NH 4 NO 3 1 g / L, K 2 HPO 4 1.2 g / L, KH 2 PO 4 0.2 g / L, NaCl 0.1 g / L, MgSO 4 · 7H 2 O 0.1 g / L, MnSO 4 H 2 O 0.1 g / L, FeSO 4 7H 2 O was prepared at 0.05 g / L and incubated for 3 days at an initial pH of 7-8, 30 ℃. In order to separate the cells from the culture solution in the fermentor (jar fermentor), the culture solution was diluted 10-fold and centrifuged (12,000 × g) to remove the cells. To the supernatant from which the cells were removed, 95% ethanol was added to be three times higher than that of the supernatant, and the mixture was left at 4 ° C. for 2 hours to separate a polysaccharide having a white precipitate. The polysaccharide thus separated was named A8 (A8). A8 polysaccharide was added to distilled water, and the solution was dissolved in water. The remaining ethanol was completely removed using a reduced pressure evaporator, and then lyophilized to prepare a white powder.
실시예 4: 분자량의 측정Example 4: Determination of Molecular Weight
정제된 에이8 다당류의 분자량을 측정하기 위해 HPLC[Shimdazu Co. JP]에 PL-GFC 1000Å(8 ㎛, 300 ×7.5 ㎜, Polymer Lab., USA) 컬럼을 부착하고 3차 증류수를 용매로 사용하여 25 ℃에서 1 ㎖/min의 유속으로 굴절률 검출기(refraction index detector) RID-6A로 검출한 결과, 에이8의 평균분자량은 7백만 달톤(dalton) 정도로 추정된다[도 2]. 도 2에서 logY=aX=b 일 때 a= -1.2316, b= 14.9598.r2= 0.9643 이였다.To determine the molecular weight of purified A8 polysaccharide, HPLC [Shimdazu Co. JP] PL-GFC 1000Å (8 ㎛, 300 × 7.5 ㎜, Polymer Lab., USA) column attached with a third distilled water as a solvent, the refractive index detector at a flow rate of 1 ㎖ / min at 25 ℃ ) As a result of detection with RID-6A, the average molecular weight of A8 is estimated to be about 7 million daltons (FIG. 2). In FIG. 2, when logY = aX = b, a = −1.2316 and b = 14.9598.r 2 = 0.9643.
실시예 5: 구성 당 분석Example 5: Analysis Per Configuration
에이8 다당류 0.1 g을 2 N TFA(trifluoroacetic acid) 10 ㎖에 용해시킨 후, 121 ℃에서 1시간 동안 가수분해하고 감압농축기를 사용하여 40 ℃에서 감압 농축하여 TFA를 완전히 제거한 다음, 실리카 겔이 피막된 TLC 플레이트(Merck, 5744)로 분석하였다. 전개용매로는 아세토니트릴(acetonitrile)/물 = 85/15 (v/v)로 전개하여 발색시약(diphenylamine/anilline/phosphoric acid)으로 100 ∼ 105 ℃에서 5분간 처리하여 나타나는 점(spot)들을 표준물질과 비교 분석하여 에이8의 구성당을 분석하였다. 에이8 다당류는 글루코오스, 퓨코오스, 글루쿠론산, 갈락토스로 구성된 헤테로다당류이고, 이들 구성성분의 몰비는 2.96 : 1.00 : 1.55 : 0.58이었다[도 3]. 세균이 생성하는 세포외 다당류들 중에서 이런 구성성분과 몰비를 가지는 다당류는 이제까지 보고된 바 없어 상기 다당류는 신규 다당류임이 확인되었다. 0.1 g of A8 polysaccharide was dissolved in 10 ml of 2N trifluoroacetic acid (TFA), and then hydrolyzed at 121 ° C. for 1 hour, and concentrated under reduced pressure at 40 ° C. using a vacuum concentrator to completely remove TFA. Were analyzed by TLC plate (Merck, 5744). As a developing solvent, acetonitrile / water = 85/15 (v / v) was developed and treated with diphenylamine / anilline / phosphoric acid for 5 minutes at 100 to 105 ° C. The composition sugar of A8 was analyzed by comparative analysis with the material. A8 polysaccharide was a heteropolysaccharide composed of glucose, fucose, glucuronic acid and galactose, and the molar ratio of these components was 2.96: 1.00: 1.55: 0.58 [FIG. 3]. Among the extracellular polysaccharides produced by bacteria, polysaccharides having a molar ratio with these components have not been reported so far, and it was confirmed that the polysaccharides are novel polysaccharides.
실시예 6: 다당류의 구조분석을 위한 IR 스펙트럼Example 6 IR Spectrum for Structural Analysis of Polysaccharides
에이8 다당류의 구조분석을 위한 적외선 흡수스펙트럼에서 다당류의 특이적인 흡수띠인 3400 ㎝-1에서 O-H 그룹, 2900 ㎝-1에서 C-H 그룹, 1700 ㎝-1과 1060 ㎝-1 부근에서 C=O 스트레칭 밴드와 C-O 스트레칭 밴드가 나타나고 있으며, 이는 당유도체인 글루쿠론산의 카복실기인 것으로 추정된다. 또한, 1400 ㎝-1에서 CH2 벤딩이 나타났으며, 1000 ㎝-1와 1200 ㎝-1 범위에서 나타나는 강한 흡수띠는 모든 당 유도체들의 전형적인 특징을 나타내었다[도 4].Infrared absorption spectra for structural analysis of A8 polysaccharides, C = O stretching bands around 3700 cm -1 to OH groups, 2900 cm -1 to CH groups, 1700 cm -1 and 1060 cm -1 , which are specific absorption bands for polysaccharides And CO stretching bands appear, presumably the carboxyl group of glucuronic acid, a sugar derivative. In addition, CH 2 bending was observed at 1400 cm −1 , and the strong absorption bands in the range of 1000 cm −1 and 1200 cm −1 showed typical characteristics of all sugar derivatives [FIG. 4].
실시예 7: 다당류의 물성학적 특성Example 7 Physical Properties of Polysaccharides
에이8 다당류의 사료첨가용도로 사용가능성을 조사하기 위해 물성학적 특성을 여러 조건에서 다당류의 점도를 브룩필드 전류계 DV-Ⅲ(Brookfield engineering Lab. INC USA)를 사용하여 측정하였다. 점도측정은 스핀들(spindle) SC4-34[Brookfield model DVⅢ-rheometer, SC4-34, 30 rpm, RT]를 사용하여 0.5 rpm에서 150 rpm까지 측정하였다. In order to investigate the applicability of A8 polysaccharide as a feed additive, the viscosity of the polysaccharide under various conditions was measured using a Brookfield ammeter DV-III (Brookfield engineering Lab. INC USA). Viscosity measurements were measured from 0.5 rpm to 150 rpm using a spindle SC4-34 (Brookfield model DVIII-rheometer, SC4-34, 30 rpm, RT).
(1) 농도별 점도 측정(1) Measurement of viscosity by concentration
정제된 에이8 다당류를 증류수에 1, 2, 3, 4, 5%가 되도록 녹인 다음, 스핀들(spindle) SC4-34[Brookfield model DVⅢ-rheometer, SC4-34, 30 rpm, RT]를 장착하여 0.5 rpm에서 150 rpm까지 점도를 측정하여 다음 표 2에 나타내었다. 각 농도별에 대한 30 rpm에서 측정된 겉보기 점도는 각각 25, 75, 125, 200, 280 cP로 측정되어 에이8 다당류의 농도증가와 겉보기 점도의 증가는 비례적이었다.The purified A8 polysaccharide was dissolved in distilled water to 1, 2, 3, 4, 5%, and then mounted with a spindle SC4-34 [Brookfield model DVIII-rheometer, SC4-34, 30 rpm, RT] The viscosity was measured from rpm to 150 rpm and is shown in Table 2 below. The apparent viscosities measured at 30 rpm for each concentration were 25, 75, 125, 200, and 280 cP, respectively, and the concentration increase and apparent viscosity of A8 polysaccharides were proportional to each other.
(2) 온도별 점도 측정(2) Viscosity measurement by temperature
정제된 에이8 다당류의 온도별 점도를 조사하기 위하여 에이8 다당류의 농도를 2% 되도록 15 ㎖의 증류수에 녹여 실온(25 ℃)에서 85 ℃까지의 온도범위에서 30분간 열처리한 다음, 각각의 그 온도에서 스핀들 SC4-34로 겉보기 점도를 측정하여 다음 표 3에 나타내었다. 에이8 다당류는 50 ℃까지 겉보기 점도의 감수율이 약 15%였고, 85 ℃까지의 감수율이 약 30%였다. 에이8 다당류는 온도영향에 따라서 겉보기 점도가 감소하였다. 이는 일반적인 다당류에 나타나는 온도별에 대한 물성적 성질과 유사한 결과이다.In order to investigate the temperature-specific viscosity of the purified A8 polysaccharide, the concentration of A8 polysaccharide was dissolved in 15 ml of distilled water such that the concentration of A8 polysaccharide was 2%, and heat-treated at room temperature (25 ° C.) to 85 ° C. for 30 minutes. The apparent viscosity was measured with spindle SC4-34 at temperature and is shown in Table 3 below. The A8 polysaccharide had an apparent viscosity loss of about 15% up to 50 ° C and a 30% loss up to 85 ° C. A8 polysaccharides showed a decrease in apparent viscosity with temperature. This result is similar to the physical properties of the temperature according to the general polysaccharides.
(3) pH별 점도 및 안정성 측정(3) Measurement of viscosity and stability by pH
pH별 점도측정은 에이8 다당류의 농도를 2%로 하고 1N NaOH와 1N HCl용액으로 pH를 2에서 11까지 조절하면서 겉보기 점도를 측정하였다. pH에 대한 에이8 다당류의 안정성 측정은 pH를 2 ∼ 11까지 조절한 다음, 24시간 후에 다시 점도를 측정하여 pH에 대한 안정성을 조사하여 다음 표 4에 나타내었다.Viscosity measurement for each pH was measured as the concentration of A8 polysaccharide 2% and the apparent viscosity was adjusted by adjusting the pH from 2 to 11 with 1N NaOH and 1N HCl solution. Measurement of the stability of the A8 polysaccharide to pH was adjusted to 2 to 11, and then measured again after 24 hours to measure the stability of the pH is shown in Table 4 below.
에이8 다당류는 전 pH범위에서 겉보기 점도의 변화가 거의 없었으며, 안정성 실험에서도 같은 결과를 나타내었다. 이런 결과는 사료첨가제의 유익균(유산균) 코팅제로 사용할 경우, 산업동물(양돈, 양계)의 위에서 생존율을 높여 장내에 도달하는 효율을 증대시킬 수 있을 것으로 기대된다. 또한, 이런 결과는 다른 다당류가 갖지 못하는 상당히 특징적인 물성적 성질이며, 응용용도에서 여러 가지 제제화에 용이하게 이용될 수 있는 특징이다.A8 polysaccharide showed little change in apparent viscosity over the entire pH range, and the same results were obtained in the stability experiment. This result is expected to increase the efficiency of reaching the intestine by increasing the survival rate in industrial animals (swine, poultry) when used as a beneficial bacteria (lactic acid bacteria) coating of feed additives. In addition, these results are quite characteristic physical properties that other polysaccharides do not have, and can be easily used for various formulations in application.
(4) 온도별 안정성 측정(4) Temperature stability measurement
온도별 점도측정은 에이8 다당류의 농도를 2%로 하고 온도범위 25 ℃(실온)에서 85 ℃까지 하여 1시간 동안 열처리한 다음, 실온으로 냉각된 후에 점도를 측정하였다. 121 ℃의 열처리는 가압멸균기을 이용하여 15분간 처리한 다음, 실온으로 냉각된 후에 점도를 측정하여 다음 표 5에 나타내었다. 에이8 다당류는 전 온도범위에서 상당히 안정하며, 특히 가압멸균기로 열처리하여도 겉보기 점도가 안정한 결과를 보였다. 이런 결과는 에이8 다당류만이 가지는 독특한 물성적 특징이며, pH에 대한 안정성의 결과 마찬가지로 사료첨가제의 제제화 과정에서 열을 가하는 공정에서 유산균의 생존율을 높일 수 있을 것으로 기대됨과 동시에 여러 가지 제제화에 상당히 용이함을 더욱 부각시키는 결과이다.Viscosity measurement by temperature was a 2% concentration of A8 polysaccharide and heat-treated for 1 hour at a temperature range of 25 ° C (room temperature) to 85 ° C, and the viscosity was measured after cooling to room temperature. The heat treatment at 121 ℃ was treated for 15 minutes using an autoclave, and after cooling to room temperature to measure the viscosity is shown in Table 5 below. A8 polysaccharides were quite stable over the entire temperature range, and the apparent viscosity was stable even after heat treatment with autoclave. This result is a unique physical property of A8 polysaccharide, and as a result of stability to pH, it is expected to increase the survival rate of lactic acid bacteria in the process of applying heat during the formulation of feed additives, and is very easy to formulate various formulations. This is the result of further highlighting.
(5) 염에 대한 호화성(Salt compatability) 측정 (5) Salt compatability measurement for salt
에이8 다당류의 용액을 이용한 각종 염에 대한 호화성(compatability)을 측정하기 위해 NaCl, KCl, CaCl2, FeCl3를 농도별로 5, 10, 15%로 첨가하여 점도를 측정하였다. 양이온의 1가와 2가에 대한 에이8 다당류의 호화성은 염의 농도가 증가하여도 점도의 변화가 없는 것으로 조사되었나, 3가 양이온의 경우는 농도가 증가할수록 감소경향을 나타내었다[도 5]. 이러한 결과는 염과의 호화성(salts compatability)이 아주 높아 산업동물(양돈, 양계 등)의 장내에서 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진에 특이적인 작용하며 장내의 항상성을 유지하여 장내 유익균의 사멸을 제어할 수 있다. 또한, 다당류의 면역활성조절능에 의한 항병력 증가로 항생제의 오남용에 의한 병원균의 내성력 증가를 억제하여 질병발병을 감소시킬 수 있을 것으로 기대된다.In order to measure the compatibility of various salts using a solution of A8 polysaccharide, NaCl, KCl, CaCl 2 , and FeCl 3 were added at 5, 10, and 15% concentrations to measure viscosity. Gelatinization of the A8 polysaccharides for monovalent and divalent cations did not change the viscosity even with increasing salt concentration, but in the case of trivalent cations, the concentration tended to decrease with increasing concentration [Fig. 5]. These results show that the salts compatability is very high, so it is specific to the constant intestinal action and the improvement of the treatment of digestive disorders in the intestines of industrial animals (swine, poultry, etc.) and to promote recovery and maintain the intestinal homeostasis. The killing of enterococci can be controlled. In addition, it is expected to reduce the onset of the disease by inhibiting the increase in the resistance of pathogens due to the misuse of antibiotics by increasing the anti-pathology due to the ability to modulate the immune activity of polysaccharides.
실시예 7 : 사료첨가제로의 이용가능성 검토Example 7 Review of Applicability as a Feed Additive
열과 pH 안정성, 염과의 호화성이 뛰어난 상기 다당류를 0.5%중량으로 문제의 돈군에 경구 투여한 결과, 가축의 장내에 항상성을 일정하게 유지하여 설사증, 회장염, 유행성 설사증 등에 호전과 회복증상을 보였다[표 6]. As a result of oral administration of the above-mentioned polysaccharides having excellent heat, pH stability and salt luxury to the pig group in question at 0.5% by weight, homeostasis was maintained in the intestine of the livestock to improve diarrhea, ileitis, and epidemic diarrhea. [Table 6].
이상에서 설명한 바와 같이, 본 발명에 따른 신균주 바실러스 속 에이8(Bacillus sp. A8)로부터 생산되는 다당류로 사료첨가제를 제조하면 산업동물(양돈, 양계 등)의 장내의 일정한 정장작용 효과와 소화장애 치료효과 상승 및 회복촉진 및 고기능성 다당류의 면역활성능에 의한 항병력 증가로 인해 항생제의 오남용에 의한 장내 유익균의 사멸과 병원균의 내성 증가에 의한 질병 발병을 억제할 수 있어 축산업에 매우 유용하리라 기대된다.As described above, when the feed additive is prepared from the polysaccharide produced from the new strain Bacillus sp. A8 according to the present invention, the intestinal constant effect on the intestines and digestive disorders of industrial animals (swine, poultry, etc.) It is expected to be very useful for livestock industry because it can suppress the death of beneficial intestinal bacteria and increase disease resistance due to misuse of antibiotics due to the increase of therapeutic effect and promotion of recovery and the increase of anti- potency due to immune activity of high functional polysaccharides. .
도 1은 신균주 바실러스 속 에이8의 전자 현미경사진을 나타낸 것이다.Figure 1 shows an electron micrograph of A8 strain genus Bacillus.
도 2는 HPLC를 이용하여 겔 통과 컬럼(Gel Permeation column)으로 분석한 에이8 다당류의 분자량을 측정한 것이다[O: 에이8 다당류, □: 200만 달톤 덱스트란, △: 58만 달톤 덱스트란, ▽: 14.3만 달톤 덱스트란, ◇: 7.3만 달톤 덱스트란, : 1.5만 달톤 덱스트란].2 is a molecular weight of the A8 polysaccharide analyzed by a gel permeation column using HPLC [O: A8 polysaccharide, □: 2 million Dalton dextran, △: 580,000 Dalton dextran, ▽: 14.33 million Dalton dextran, ◇: 7.30,000 Dalton dextran, : 1.50,000 Dalton dextran].
도 3은 TLC로 에이8 다당류의 구성성분을 분석한 것이다[A: 글루코스, B: 갈락토스, C: 글루코사민, D: 에이8 다당류, E: 표준물질의 혼합체, F:글루쿠론산, G: 퓨코오스].Figure 3 is a component analysis of the A8 polysaccharide by TLC [A: glucose, B: galactose, C: glucosamine, D: A8 polysaccharide, E: mixture of standards, F: glucuronic acid, G: Pew Coos].
도 4는 에이8 다당류의 구조를 분석한 IR 스펙트럼을 나타낸 것이다.Figure 4 shows the IR spectrum of the structure of the A8 polysaccharide.
도 5는 바실러스 속 에이8이 생산하는 에이8 다당류의 염에 대한 호화성을 나타낸 것이다.Figure 5 shows the gelatinization of the salt of the A8 polysaccharide produced by the genus A8 Bacillus.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0019277A KR100494808B1 (en) | 2003-03-27 | 2003-03-27 | Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0019277A KR100494808B1 (en) | 2003-03-27 | 2003-03-27 | Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040084303A KR20040084303A (en) | 2004-10-06 |
KR100494808B1 true KR100494808B1 (en) | 2005-06-13 |
Family
ID=37367891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0019277A Expired - Fee Related KR100494808B1 (en) | 2003-03-27 | 2003-03-27 | Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100494808B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100738007B1 (en) * | 2005-11-22 | 2007-07-13 | 부경대학교 산학협력단 | New Microbial Bacillus Berechens A-68 and Uses thereof |
KR101447461B1 (en) * | 2013-03-04 | 2014-10-06 | 서울대학교산학협력단 | A method for producing pectin extracts from rapeseed cake using enzymatic hydrolysis therefor |
-
2003
- 2003-03-27 KR KR10-2003-0019277A patent/KR100494808B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20040084303A (en) | 2004-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1305399B1 (en) | Bacillus subtilis var. chungkookjang producing high molecular weight poly-gamma-glutamic acid | |
AU2011230685B2 (en) | Anti-allergic agent | |
Murata et al. | Bacterial alginate lyase: enzymology, genetics and application | |
WO2013123791A1 (en) | Bacillus, hyaluronic acid enzyme, and uses thereof | |
US10738275B2 (en) | Paenibacillus sp. strain, cultivation method and use of the same | |
JP4642050B2 (en) | Novel chlorella, method for producing the same and health food containing the chlorella | |
US20150290257A1 (en) | Method of enhancing hyaluronic acid secretion using probiotic strain | |
KR102581542B1 (en) | Novel streptococcus strain and hyaluronidase derived from the same | |
KR100494808B1 (en) | Bacillus sp. A8 that is produced the polysaccharide, its application or polysaccharide produced from the same strain | |
KR101854705B1 (en) | Novel strains of Bacillus licheniformis NY1505 producing high amount of α-glucosidase inhibitors | |
US6436680B1 (en) | Marine bacterial strain of the genus vibrio, water-soluble polysaccharides produced by said strain and their uses | |
Singh et al. | Optimization and characterization of exopolysaccharides produced by lactobacillus strains isolated from cabbage and cucumber | |
KR100472007B1 (en) | Microorganism producing hyaluronic acid and method of producing hyalironic acid using thereof | |
Yu et al. | Corynebacterium defluvii sp. nov., isolated from Sewage | |
KR101727251B1 (en) | Pseudomonas geniculata KCTC12651BP having the Ability to Degrade Green Algae derived Polysaccharides | |
KR20090060510A (en) | Pediococcus pentosaceus gen 1 having antimicrobial activity and microbial agent comprising the same | |
KR20090072145A (en) | Weissella virideskens Gen 2 with antimicrobial activity and microbial agent containing the same | |
CN107937309B (en) | A kind of Propionibacterium and its application in production folic acid and niacin | |
JP5090805B2 (en) | Novel microorganism, method for decomposing hyaluronic acid or salts thereof using novel microorganism, and method for producing unsaturated hyaluronic acid sugar chain using novel microorganism | |
KR100462904B1 (en) | Manufacturing process for producing Alginate lyase using Xanthomonas sp. BH-1, newly isolated marine bacterium | |
KR102780203B1 (en) | Paenibacillus strain and new enzyme derived from the same | |
JPH0443637B2 (en) | ||
KR920009494B1 (en) | New Streptococcus microorganisms and method for producing high molecular weight hyaluronic acid using the same | |
KR101081745B1 (en) | Staphylococcus saprophyticus BMSZ711 producing poly-Ν-acetylglucosamine and method for producing poly―Ν―acetylglucosamine from Staphylococcus saprophyticus BMSZ711 | |
JP4402574B2 (en) | Mutanase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030327 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041124 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050524 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050602 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20050603 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20080523 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20090601 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20100603 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20110602 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20120524 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20120524 Start annual number: 8 End annual number: 8 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |